Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

With the release of the Company Report for 2020, N4 Pharma’s CEO, Nigel Theobald, has spoken to Directors Talk about the highlights of last year year. He provides an update on our new refined strategy to focus on three work streams and explains what the Patent in relation to Nuvec® means for the company.

DirectorsTalk interview: N4 Pharma making ‘considerable’ progress